Drug Type Prophylactic vaccine, Dendritic cell vaccine |
Synonyms Acute myeloid leukaemia vaccine, Leukemic dendritic cell vaccine, Vididencel + [3] |
Target- |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationFast Track (US), Orphan Drug (EU) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Myeloid Leukemia | Phase 2 | NL | 15 Oct 2018 | |
Acute Myeloid Leukemia | Phase 2 | SE | 15 Oct 2018 | |
Acute Myeloid Leukemia | Phase 2 | NO | 15 Oct 2018 | |
Acute Myeloid Leukemia | Phase 2 | FI | 15 Oct 2018 | |
Acute Myeloid Leukemia | Phase 2 | DE | 15 Oct 2018 | |
Residual Neoplasm | Phase 2 | DE | 15 Oct 2018 | |
Residual Neoplasm | Phase 2 | NL | 15 Oct 2018 | |
Residual Neoplasm | Phase 2 | FI | 15 Oct 2018 | |
Residual Neoplasm | Phase 2 | SE | 15 Oct 2018 | |
Residual Neoplasm | Phase 2 | NO | 15 Oct 2018 |
Phase 2 | 20 | (vmmgmqboze) = none cenrgpqpwx (zbhyfxlpnr ) View more | Positive | 11 Dec 2023 | |||
NCT01373515 (Literature) Manual | Phase 1 | 12 | (Responder) | (pjpnjbqibw) = wzimkehiyx nxgzvkzcaq (rotqbujppx, 90–1849) View more | Positive | 02 Nov 2023 | |
(Non-responder) | (pjpnjbqibw) = pzeazzvwne nxgzvkzcaq (rotqbujppx ) View more | ||||||
Phase 2 | Acute Myeloid Leukemia Maintenance | 20 | (yyzsiuvnxb) = novrbhscks sfvuvcbulb (bbiegsqwcw ) View more | Positive | 16 May 2022 | ||
NCT01373515 (ASH2019) Manual | Phase 1 | 12 | (owwnvdwwdr) = ylbocrvuof jonadersmn (bgrgvbafdd ) View more | Positive | 13 Nov 2019 |